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ResistanceIn this issue of EBioMedicine, Sanjeev Krishna and colleagues com-
pared oral artesunate to placebo to treat colorectal cancer (Krishna
et al., 2014). While the number of included patients was limited, they
found a trend to higher recurrence-free survival probability at 42
months of follow-up after artesunate treatment. They failed to demon-
strate that artesunate restored apoptosis in cancer cells, but they ob-
served a decrease expression of Ki67 prognosis marker of colorectal
cancer (Krishna et al., 2014). This double-blinded trial provides
further evidence that artemisinin derivatives (ARTs) are not only anti-
malarial drugs. Do these data open new opportunities or drive new
problems to malaria-endemic areas?
Evidence has emerged years ago that ARTs present a wide range of
biological activities based on their alkylating capabilities, andmay be ef-
fective against cancer cells by induction of cell apoptosis caused by reac-
tive oxygen species production and angiogenesis inhibition (Hamacher-
Brady et al., 2011). ARTs show potent in vitro activity for a variety of
cancer cell lines (68 cell lines derived from solid tumors and 24 cell
lines derived from hematological malignancies) at concentrations that
are established or reachable in patients (Hooft van Huijsduijnen et al.,
2013). Based on these in vitro results and the well-established safety
of ARTs, evaluation of anticancer effect of ARTs in a clinical setting is
warranted. One could expect such studies to be conducted in northern
high-income countries free of malaria.
In southern low-income endemic areas, malaria still causes an unac-
ceptable mortality rate and is responsible for more than half a million
deaths each year, mainly in sub-Saharan Africa and in children under
5 years of age (O'Meara et al., 2010). Eliminating malaria requiresDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.11.010.
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good drug at the right dose, and future mass vaccination. Considerable
advancements have been made but malaria elimination still needs uni-
versal access to these strategies. Artemisinin and its derivatives have
been the drugs of choice to treat malaria all over the world for more
than a decade. These sesquiterpene lactones, including artesunate,
artemether, arte-ether, dihydroartemisin, have demonstrated higher ef-
ﬁcacies than all other known antimalarial drugs such as quinine. ARTs
proved to have excellent tolerability in many controlled studies. While
concerns have emerged in the early 2000s from animal studies when
high doses were associated with damages to brainstem nuclei, the safe-
ty of short-term treatments with ARTs is well documented. ARTs saved
millions of people from this devastating parasitic disease, and will con-
tinue to be used for that assignment.
Themajor drawback of ARTs is the potential ofmalaria parasites to es-
cape from treatment after a few days, favoring the selection of drug-
resistant parasites. This is the reason of the introduction of artemisinin-
based combined therapies (ACTs) to treat malaria. These treatments are
based on the association of ART that rapidly kills the parasites, and a
partner drug with a prolonged half-life to complete the cure. The
World Health Organization withdrawal of artemisinin monotherapy in
malaria-endemic areas did not prevent the spread of drug resistance
in South-East Asia (Ashley et al., 2014).While this resistance is still lim-
ited and efforts aremade to contain its spread, ART use is put under sur-
veillance (Talisuna et al., 2012).What will be the issues of using ARTs to
treat other diseases? Is it only a geographical matter: cancer treatment
in the north, malaria treatment in the south?
ARTs also showed μMactivities against other parasites (Schistosoma,
Toxoplasma and Trypanosoma), viruses (herpes virus, hepatitis B and
hepatitis C viruses) and fungi (Cryptococcus), although clinical used in
humans is mainly restricted to schistosomiasis so far. Schistosomiasis
is the second most devastating parasitic disease in the world, leading
to chronic and debilitating disease affecting 200million people. Repeat-
ed prophylactic doses of ARTs dramatically reduce egg production and
prevent 65–97% schistosomiasis cases. Toxoplasmosis is a serious con-
cern during pregnancy and immunosuppression. In vitro, ARTs showed
high efﬁcacy against the parasite (Hencken et al., 2010), and mortality
was reduced in a murine model of toxoplasmosis (Dunay et al., 2009).
African and American trypanosomiases are severe diseaseswith a treat-
ment hampered by high toxicity. Preliminary in vitro data showed that
ARTs could be effective against these parasites (Nibret andWink, 2010).
Double-stranded DNA herpes viruses are very common and cause
severe infections in immunocompromised patients. ARTs have shown
1–15 μM in vitro activity against cytomegalovirus and a rapid virusthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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plantation (Shapira et al., 2008). Taken altogether, these recent ad-
vances open new opportunities for a broader use of ARTs in tropical
and non-tropical areas to treat several infectious diseases, besides
malaria.
Considering the current study presented by Krishna et al. and other
clinical studies, ARTsmay also be used to treat different types of cancers
in the future. One could speculate that these drugs may be mostly used
in areas with a high-grade medical care, which should be malaria free.
Thus the potential for these treatments to increase the spread of drug-
resistantmalaria parasite is considerably restricted by this epidemiolog-
ical and economical difference. However, if the beneﬁt of ARTs in cancer
patients in conﬁrmed, how will the prospect of using these drugs to
treat cancer patients in malaria-endemic areas be addressed? How
will we handle the access to artesunate treatment of colorectal cancer
patients in countries such as Kenya, Thailand and Indonesia to limit
the risk of selection of malaria-resistant parasites in asymptomatic car-
riers? Shouldwe perform systematic high-sensitivemalaria diagnosis in
cancer patients before induction of treatment? Will it be necessary to
add a partner drug in endemic areas and what will be the effects on
cancer?
Artemisinins are demonstrating vast therapeutic potential for a large
array of different diseases. Will the good news of a new usage for anti-
cancer treatment open the Pandora's box for transmissible diseases? A
controlled and sustainable use of new medication is required to limit
the risks.
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